EMA Adopts a Positive Opinion for Biosimilar Denosumab By Ogkologos - May 28, 2025 540 0 Facebook Twitter Google+ Pinterest WhatsApp Jubereq is a biosimilar of Xgeva, which was authorised in the EU in 2011 Source RELATED ARTICLESMORE FROM AUTHOR The Legacy of the ESMO Patient Engagement Summit 2025: Advancing Rights of Patients with Cancer via Cross-Border Best Practices and Collaboration Sustained PFS Benefit of Imlunestrant Over SoC in Patients with ESR1-mutated Advanced Breast Cancer ESMO Welcomes Launch of Health Package Introducing EU Measures That Can Boost Innovation in Oncology and Help Prevent New Cancer Cases MOST POPULAR Bariatric Surgery May Reduce the Risk of Some Common Cancers December 2, 2022 FDA Approves Lisocabtagene Maraleucel for Second-Line Treatment of Large B-Cell Lymphoma July 12, 2022 A bug in the system – the difficulties of linking the... June 2, 2021 Genetic Testing for Bladder Cancer: What People With Cancer and Their... March 23, 2023 Load more HOT NEWS Heine H. Hansen Award: Johan Vansteenkiste and Fiona Blackhall Honoured for... Feasibility and Preliminary Efficacy Results of the Beat AML Study The rise of the ‘long-waiter’ – why cancer waiting times are... Breast Cancer Survivor Fights Back After Instagram Bans Photos of Her...
